Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12560352 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA | |
| SCHEMBL732491 | 0.86 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA | |
| SCHEMBL9604072 | 0.77 | PIK3CD (0.84) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA | |
| SCHEMBL733839 | 0.76 | PIK3CD (0.75) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA | |
| SCHEMBL734099 | 0.76 | PIK3CG (0.59) | PIK3CDPIK3CGPIK3CBL3MBTL1 | |
| SCHEMBL18923577 | 0.76 | L3MBTL1 (0.69) | PIK3CDPIK3CGPIK3CBL3MBTL1 | |
| SCHEMBL27764713 | 0.75 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3CBPIK3R1L3MBTL1 | |
| SCHEMBL733167 | 0.75 | PIK3CD (0.86) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA | |
| SCHEMBL733097 | 0.74 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA | |
| SCHEMBL733332 | 0.73 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CHEN YI | 2011-06-23 | — | — | US | disclosed |
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | CHEN YI | 2011-06-23 | — | — | US | disclosed |
| US-7919498-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919498-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919498-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-2132207-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090030002-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030002-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030002-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008118454-A2 | DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118454-A2 | DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152277-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CG 54/4885PIK3CB 35/4885 |
| US-20090030002-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 15/4885PIK3CG 53/4885PIK3CB 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.